Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Management of Methotrexate During Active Infection

Immediate Management During Active Infection

  • Methotrexate should be temporarily discontinued during severe infection or when infection is not responding to standard treatment, and can be restarted once the infection has cleared, as recommended by clinical guidelines 1
  • Discontinue methotrexate immediately in patients with severe infection or infection not responding to standard antimicrobial therapy, to prevent further immunosuppression 1
  • Permanently discontinue methotrexate if opportunistic infections develop, such as Pneumocystis jirovecii pneumonia, due to the high risk of severe complications 1

Clinical Assessment During Infection

  • Obtain complete blood count with differential to assess for neutropenia or other cytopenias that may complicate infection management, and monitor closely 1
  • Monitor renal function closely, as decreased renal function can lead to increased methotrexate levels and toxicity, particularly problematic during acute illness 1
  • Monitor patients carefully for signs of sepsis and treat accordingly, to prevent severe outcomes 1

Evidence Supporting Temporary Discontinuation

  • Methotrexate increases infection risk, particularly for pneumonia, skin/soft tissue infections, and urinary tract infections, with most infections occurring within the first 18 months of treatment 1

Restarting Methotrexate After Infection Resolution

  • Restart methotrexate when the infection has completely cleared, and ensure renal function has normalized before restarting, to minimize the risk of toxicity 1
  • Resume regular monitoring schedule after restarting therapy, including complete blood count every 2-3 months once therapy is stabilized 1

Special Considerations During Infection Management

  • Avoid co-trimoxazole, trimethoprim, and other antifolate drugs during methotrexate therapy due to risk of severe bone marrow suppression, particularly during infection 1
  • Use extreme caution in patients with comorbidities that increase infection risk, such as diabetes, and consider alternative treatments 1
  • Patients with HIV or hepatitis require particularly careful consideration, due to the increased risk of severe infections and complications 1

Contrast with ACR Guidelines

  • The American College of Rheumatology guidelines address previous serious infection, rather than active infection, and recommend addition of conventional synthetic DMARDs over biologics or targeted synthetic DMARDs for patients with moderate-to-high disease activity 2

Common Pitfalls to Avoid

  • Do not continue methotrexate through severe infection, as this may prevent adequate immune response and increase the risk of severe complications 1
  • Do not use trimethoprim-containing antibiotics in patients on methotrexate, due to the risk of synergistic antifolate effects causing potentially fatal bone marrow suppression 1
  • Do not restart methotrexate prematurely, before infection has completely resolved and renal function normalized, to minimize the risk of toxicity and complications 1

Management of Methotrexate and Antibiotic Interactions

Introduction to Methotrexate Management

  • The British Association of Dermatologists recommends stopping methotrexate immediately if a patient has a severe infection or an infection not responding to standard treatment, and restarting only after the infection has completely cleared and the antibiotic course is complete 3, 4
  • The British Association of Dermatologists explicitly states that methotrexate should be stopped temporarily during severe infection or when infection is not responding to standard treatment 3

Methotrexate and Amoxiclav Interactions

  • Penicillins, including amoxicillin, can increase methotrexate levels and toxicity through reduced renal elimination and competition at the renal tubular secretion pathway 4
  • The British Association of Dermatologists lists penicillins among drugs that may increase methotrexate toxicity even at low doses 4

Patient Risk Factors

  • Patients with advanced age, renal impairment, or lack of folate supplementation are at higher risk for methotrexate-induced toxicity, and low-dose methotrexate is associated with increased risk of certain infections 3
  • Low-dose methotrexate is associated with increased risk of pneumonia, skin/soft tissue infections, and urinary tract infections, with most infections occurring within the first 18 months of treatment 3

UTI Treatment in Patients on Methotrexate

Methotrexate Management

  • The British Association of Dermatologists recommends stopping methotrexate if antibiotics are given for severe infection or infection not responding to standard treatment, continuing the hold until the patient recovers and the antibiotic course is complete 5

Antibiotic Selection

  • The British Association of Dermatologists explicitly advises against using trimethoprim, co-trimoxazole (trimethoprim-sulfamethoxazole), or other antifolate antibiotics in patients on methotrexate due to synergistic antifolate effects causing potentially fatal bone marrow suppression 5
  • Penicillins (including amoxicillin and amoxicillin-clavulanate) can increase methotrexate toxicity through reduced renal elimination and competition at renal tubular secretion pathways, as noted by the British Association of Dermatologists 5
  • Ciprofloxacin and tetracyclines have been shown to increase methotrexate levels in high-dose contexts, though less problematic in low-dose methotrexate therapy, according to the British Association of Dermatologists 5
  • The British Association of Dermatologists suggests considering cephalosporins or fosfomycin as first-line agents for uncomplicated UTI in patients on methotrexate, as these have fewer documented interactions with methotrexate 5

Patient Monitoring

  • Drug interactions are significantly more dangerous in patients with reduced renal function, as methotrexate elimination is principally renal, as stated by the British Association of Dermatologists 5

Restarting Methotrexate

  • The British Association of Dermatologists recommends restarting methotrexate only when the antibiotic course is complete 5

Common Pitfalls to Avoid

  • The British Association of Dermatologists warns against using trimethoprim-containing antibiotics under any circumstances in methotrexate patients, as this combination can cause fatal bone marrow suppression 5

Management of Methotrexate During Active Herpes Infection

Immediate Management of Active Herpes (HSV or VZV)

Evidence level: Expert consensus and clinical practice guidelines (moderate strength).

Guideline Society Recommendations

Evidence level: Guideline consensus (strong recommendation).

Criteria for Restarting Methotrexate After Herpes Resolution

Evidence level: Consensus‑based clinical guidance (moderate strength).

Long‑Term Herpes Zoster Risk With Methotrexate

Evidence level: Observational cohort study (moderate evidence).